Immune Reconstitution and Long-Term Immunologic Changes Following Transitionfrom anti-CD20 Therapy
Study of OCR/RTX vs. Diroximel for Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)
Sponsor: Biogen
Enrolling: Male and Female Patients
IRB Number: AAAU2756
Contact: Kaho Onomichi: 212-305-2434 / mscenter_neuro@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to beginning DRF. Baseline visit for individuals remaining on OCR/RTX will take place prior to OCR/RTX dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments.
Investigator
Rebecca Straus Farber, MD
Do You Qualify?
Are you between the ages of 18-60? Yes No
Have you been diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)? Yes No
Have you been on Ocrelizumab/Ocrevus (OCR) or Rituximab/Rituxan (RTX) for at least 2 years? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kaho Onomichi
mscenter_neuro@cumc.columbia.edu
212-305-2434
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE